FDA grapples with AI regulation for mental health apps and medical devices

The U.S. Food and Drug Administration (FDA) has authorized more than 1,900 digital health devices, but the rapid rise of AI‑driven mental‑health applications—such as chatbots and self‑care tools—has outpaced existing oversight. Many of these products reach consumers without clear validation, prompting concerns about safety, reliability, and the need for a balanced regulatory approach that protects vulnerable users while fostering innovation.

Simultaneously, FDA scrutiny of AI and machine‑learning components in medical devices is intensifying. Traditional failure‑mode and effects analysis (FMEA) methods, designed for deterministic hardware, miss AI‑specific hazards such as model drift, edge‑case errors, and silent performance degradation. A proposed four‑step framework adapts ISO 14971 and IEC 62304 risk‑management standards to identify AI‑specific hazards, recalibrate severity and occurrence scoring, and integrate continuous‑learning risks, aiming to reduce regulatory risk and accelerate approvals.